Valeritas (VLRX) Sees FY Revenue in-Line with Prior Guidance

Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2017. Valeritas expects full year 2017 revenue to reach $20 million, in line with prior guidance. Fourth quarter revenue is expected to be approximately $5.6 million, which would represent growth of 16% year-over-year and 10% sequentially.

This financial information is preliminary and subject to completion of the company’s year-end financial reporting processes and audit. Valeritas intends to report its full year and fourth quarter 2017 financial results in February and will provide the anticipated report date in a subsequent press release.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Raymond James Starts Tonix Pharma (TNXP) at Strong Buy
• ICON plc (ICLR) PT Raised to $150 at BofA Securities